We are live on ! Find out more
EA

Emerald Advisers Portfolio holdings

AUM $3.16B
1-Year Est. Return 109.58%
This Fund
S&P 500
This Quarter Est. Return
+11.43%
1 Year Est. Return
+109.58%
3 Year Est. Return
+352.93%
5 Year Est. Return
+451.34%
10 Year Est. Return
+3,577.15%
AUM
$2.59B
AUM Growth
+$202M
Cap. Flow
+$46.2M
Cap. Flow %
1.79%
Top 10 Hldgs %
21.22%
Holding
269
New
22
Increased
94
Reduced
105
Closed
21

Top Sells

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$26.6M
2
FTAI icon
FTAI Aviation
FTAI
+$22.8M
3
CRS icon
Carpenter Technology
CRS
+$19.1M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$17.8M
5
VAL icon
Valaris
VAL
+$16.7M

Sector Composition

Rank Sector Weight
1 Technology 24.96%
2 Healthcare 24.88%
3 Industrials 21.18%
4 Financials 12%
5 Consumer Discretionary 6.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EVER icon
76
EverQuote
EVER
$925M
$13.5M 0.52%
640,032
+399,257
+166% +$9.12M
IBP icon
77
Installed Building Products
IBP
$6.16B
$13.5M 0.52%
54,656
+1,419
+3% +$321K
UMBF icon
78
UMB Financial
UMBF
$11.1B
$12.9M 0.5%
+122,415
New +$11.9M
ACAD icon
79
Acadia Pharmaceuticals
ACAD
$4.38B
$12.8M 0.49%
830,829
+21,998
+3% +$367K
SIGI icon
80
Selective Insurance
SIGI
$5.78B
$11.8M 0.46%
+126,125
New +$11.4M
OFIX icon
81
Orthofix Medical
OFIX
$468M
$11.4M 0.44%
732,660
-1,339
-0.2% -$21.5K
ATRC icon
82
AtriCure
ATRC
$1.77B
$10.9M 0.42%
389,836
+38,421
+11% +$947K
TRIN icon
83
Trinity Capital
TRIN
$1.6B
$10.9M 0.42%
804,942
+82,001
+11% +$1.16M
CVLT icon
84
Commault Systems
CVLT
$6.12B
$10.7M 0.41%
+69,525
New +$9.79M
CWAN
85
DELISTED
Clearwater Analytics
CWAN
$10.2M 0.39%
+401,982
New +$9.04M
SKYT icon
86
SkyWater Technology
SKYT
$1.54B
$10.1M 0.39%
1,113,353
+18,423
+2% +$154K
YOU icon
87
Clear Secure
YOU
$5.65B
$9.69M 0.37%
292,257
-17,094
-6% -$441K
KALV
88
DELISTED
KalVista Pharmaceuticals
KALV
$9.68M 0.37%
835,988
+192,091
+30% +$2.42M
ZUO
89
DELISTED
Zuora, Inc.
ZUO
$9.53M 0.37%
1,105,573
-109,185
-9% -$968K
QTRX icon
90
Quanterix
QTRX
$182M
$9.32M 0.36%
719,217
+38,230
+6% +$511K
JACK icon
91
Jack in the Box
JACK
$286M
$9.31M 0.36%
200,067
+5,582
+3% +$280K
ARLO icon
92
Arlo Technologies
ARLO
$1.45B
$9.3M 0.36%
768,315
-115,732
-13% -$1.53M
KROS icon
93
Keros Therapeutics
KROS
$211M
$9.03M 0.35%
+155,545
New +$7.68M
EYE icon
94
National Vision
EYE
$1.66B
$8.78M 0.34%
805,086
-51,282
-6% -$598K
LIF
95
Life360
LIF
$4.36B
$8.72M 0.34%
221,679
+12,458
+6% +$436K
NVDA icon
96
NVIDIA
NVDA
$4.91T
$8.67M 0.34%
71,410
SYRE icon
97
Spyre Therapeutics
SYRE
$8.7B
$8.6M 0.33%
+292,569
New +$8.15M
LNW
98
DELISTED
Light & Wonder
LNW
$8.42M 0.33%
92,844
-83,590
-47% -$8.76M
FFIN icon
99
First Financial Bankshares
FFIN
$5.06B
$8.23M 0.32%
+222,507
New +$7.84M
SNCY
100
DELISTED
Sun Country Airlines
SNCY
$7.91M 0.31%
705,203
-177,109
-20% -$2M

Similar funds

Emerald Advisers's Q3 2024 Portfolio in Review

As of Q3 2024, Emerald Advisers held 269 positions worth $2.59B, up 8.5% from $2.38B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Emerald Advisers's Q3 2024 filing shows 22 new, 94 increased, 105 reduced and 21 closed positions. Its largest new stake was Avid Bioservices, Inc. Common Stock: 1,448,916 shares worth $16.5M. The largest sale was Transmedics, an estimated $26.6M.

By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 25% a quarter earlier, followed by Healthcare and Industrials.

  • Emerald Advisers's largest Q3 2024 buy was Avid Bioservices, Inc. Common Stock: 1,448,916 shares worth $16.5M.
  • Emerald Advisers added most to Fulton Financial in Q3 2024, an estimated $16.2M increase.
  • Emerald Advisers's biggest Q3 2024 reduction was Transmedics, cutting an estimated $26.6M.
  • Emerald Advisers fully exited Savers in Q3 2024, selling an estimated $9.16M.
  • Emerald Advisers's ten largest holdings make up 21% of its $2.59B portfolio in Q3 2024.
  • Emerald Advisers opened 22 new positions and closed 21 in Q3 2024.
  • Emerald Advisers's portfolio value rose 8.5% quarter-over-quarter to $2.59B.

Based on Emerald Advisers's 13F filing for Q3 2024, filed 29 Oct 2024.